Botulinum toxin type B
- Generic Name
- Botulinum toxin type B
- Brand Names
- Myobloc
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-44-2
- Unique Ingredient Identifier
- 0Y70779M1F
- Background
Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
- Indication
For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
- Associated Conditions
- Cervical Dystonia, Chronic Sialorrhea
- Associated Therapies
- -
Traumatic Brain Injury Treatment Market 2034: EMA, PDMA
The Traumatic Brain Injury (TBI) market is expected to grow significantly by 2034, driven by new therapies and increasing prevalence. Key companies include VeriNOS Pharmaceuticals GmbH and Cellvation, Inc., with treatments like Ronopterin and CEVA101. The US, EU4, UK, and Japan show varying market sizes and incident cases, with males more affected. Advances in treatment and diagnosis are improving outcomes.
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials
The article highlights the Multiple Sclerosis (MS) market, focusing on companies, treatments, and market trends. It covers MS as a chronic autoimmune disease affecting the CNS, current and emerging therapies, market size growth expectations by 2034, and key companies like Novartis, Biogen, and Hoffmann-La Roche. It also mentions recent study results and the importance of understanding MS epidemiology, treatment algorithms, and unmet medical needs.
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA
The Multiple Sclerosis (MS) market is projected to grow significantly by 2034, with key players like Novartis, Biogen, and Hoffmann-La Roche leading in treatment development. MS, a chronic autoimmune disease affecting the CNS, lacks a cure but treatments aim to manage symptoms and slow progression. Emerging therapies and ongoing studies highlight advancements in MS care.
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, and Emerging Therapies
The article highlights the Multiple Sclerosis (MS) market, focusing on companies, treatments, and market trends. It covers MS as a chronic autoimmune disease affecting the CNS, current and emerging therapies, market size growth expected by 2034, and key companies like Novartis, Biogen, and Hoffmann-La Roche. It also mentions recent studies and the importance of understanding MS epidemiology, treatment algorithms, and unmet medical needs for future market opportunities.
Traumatic Brain Injury Clinical Trials 2024: EMA, PDMA, FDA
Global efforts in Traumatic Brain Injury (TBI) treatment development are advancing, with companies like SHINKEI Therapeutics and SanBio leading in innovative therapies. The 2024 DelveInsight report highlights ongoing clinical trials, emerging drugs, and market dynamics, emphasizing the importance of early intervention and the potential impact of new treatments on TBI management.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath